
Bernard Zinman CM, MD, FRCPC, FACP
Director, Leadership Sinai Centre for Diabetes; Sam and Judy Pencer Family Chair in Diabetes Research, Mount Sinai Hospital and the University of Toronto; Professor of Medicine, University of Toronto, CanadaBiographical Sketch:
Bernard Zinman is director of the Leadership Sinai Centre for Diabetes and holds the Sam and Judy Pencer Family Chair in Diabetes Research at Mount Sinai Hospital and the University of Toronto, Canada. He is professor of medicine at the University of Toronto and senior scientist at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto. Dr Zinman completed his medical degree at McGill University in Montreal, Quebec, and received further training in endocrinology at the University of Toronto.
His main research interests include the long-term complications of diabetes, the development of new therapies for type 1 and type 2 diabetes, diabetes in aboriginal communities, and studies directed at the prevention of diabetes. He is the recipient of numerous awards and has authored more than 400 publications in national and international journals and over 60 book chapters and editorials. Notably, Dr Zinman was appointed to the Order of Canada, in recognition of his achievements in diabetes patient care and research.
Positions:
Director, Leadership Sinai Centre for Diabetes; Sam and Judy Pencer Family Chair in Diabetes Research, Mount Sinai Hospital and University of Toronto; Professor of Medicine, University of Toronto; Senior Scientist, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.
Degrees:
MD: McGill University, Montreal, Quebec
Postgraduate Training: Endocrinology, University of Toronto
Clinical Interests:
Long-term complications of diabetes; development of new therapies for type 1 and type 2 diabetes; diabetes in aboriginal communities; diabetes prevention
Disclosures
1. Serve(d) as Consultant or Advisor with: Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Astra Zeneca, BMS, Janssen, Takeda, and Sanofi Aventis
2. Receive(d) Institutional Grant Money from: Novo Nordisk, Boehringer Ingelheim, and Merck